Journal Article

Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

Anna P. Durbin and Ruth A. Karron

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 12, pages 1668-1677
Published in print December 2003 | ISSN: 1058-4838
Published online December 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/379775
Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are leading causes of viral lower respiratory tract illness in children and in high-risk adult populations. Despite decades of research, licensed vaccines for RSV and hPIVs do not exist. Recently, however, genetically engineered live attenuated RSV and hPIV candidate vaccines have been generated, several of which are already being evaluated in clinical trials. Recombinant technology allows candidate vaccines to be “fine-tuned” in response to clinical data, which should hasten the development of vaccines against these important respiratory pathogens.

Journal Article.  8314 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.